Literature DB >> 28749206

Small-molecule CB002 restores p53 pathway signaling and represses colorectal cancer cell growth.

Colby Richardson1, Shengliang Zhang1,2, Liz J Hernandez Borrero1, Wafik S El-Deiry1,2.   

Abstract

Much effort is currently focused on the p53 pathway. p53 is a key tumor suppressor, which is mutated or lost in many human cancers. Restoration of the p53 pathway holds the potential to induce selective cell death in tumor cells without harming normal cells that have intact p53 pathways. Most tumor cells express mutated p53 or suppress p53 by overexpression of MDM2. In this study, a compound referred to as CB002 with one closely related compound from the Chembridge library were evaluated for tumor cytotoxicity without affecting normal cells by restoration of the p53 pathway. A decrease of mutant p53 protein expression, restoration of inactivated p53, or some activation of p73 are candidate mechanisms this agent could cause tumor cell apoptosis and growth arrest. We further show that CB002 activates p53 pathway signaling in part via p73 in p53 mutant cancer cell lines. However, it is important to note that we have not established a role for p73 in the anti-tumor effect of CB002 or R1. CB002 causes tumor cell death with synergistic effects with traditional chemotherapeutics CPT-11 and 5-FU.

Entities:  

Keywords:  Colorectal cancer; anti-tumor effect; mutant p53; p53 rescue; small molecule

Mesh:

Substances:

Year:  2017        PMID: 28749206      PMCID: PMC5602428          DOI: 10.1080/15384101.2017.1356514

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  10 in total

1.  Autophagy controls the kinetics and extent of mitochondrial apoptosis by regulating PUMA levels.

Authors:  Jacqueline Thorburn; Zdenek Andrysik; Leah Staskiewicz; Jacob Gump; Paola Maycotte; Andrew Oberst; Douglas R Green; Joaquín M Espinosa; Andrew Thorburn
Journal:  Cell Rep       Date:  2014-03-27       Impact factor: 9.423

2.  A coordinated action of Bax, PUMA, and p53 promotes MG132-induced mitochondria activation and apoptosis in colon cancer cells.

Authors:  Wen-Xing Ding; Hong-Min Ni; Xiaoyun Chen; Jian Yu; Lin Zhang; Xiao-Ming Yin
Journal:  Mol Cancer Ther       Date:  2007-03       Impact factor: 6.261

3.  Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.

Authors:  Shengliang Zhang; Lanlan Zhou; Bo Hong; A Pieter J van den Heuvel; Varun V Prabhu; Noel A Warfel; Christina Leah B Kline; David T Dicker; Levy Kopelovich; Wafik S El-Deiry
Journal:  Cancer Res       Date:  2015-08-20       Impact factor: 12.701

4.  Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts.

Authors:  Wenge Wang; Seok-Hyun Kim; Wafik S El-Deiry
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-11       Impact factor: 11.205

Review 5.  Mutant p53: one name, many proteins.

Authors:  William A Freed-Pastor; Carol Prives
Journal:  Genes Dev       Date:  2012-06-15       Impact factor: 11.361

6.  Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells.

Authors:  Dun Li; Natalia D Marchenko; Ramona Schulz; Victoria Fischer; Talia Velasco-Hernandez; Flaminia Talos; Ute M Moll
Journal:  Mol Cancer Res       Date:  2011-04-08       Impact factor: 5.852

7.  Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells.

Authors:  Qin He; Ying Huang; M Saeed Sheikh
Journal:  Oncogene       Date:  2004-04-01       Impact factor: 9.867

Review 8.  Regulation of p73 activity by post-translational modifications.

Authors:  F Conforti; A E Sayan; R Sreekumar; B S Sayan
Journal:  Cell Death Dis       Date:  2012-03-15       Impact factor: 8.469

Review 9.  Anticancer drugs for the modulation of endoplasmic reticulum stress and oxidative stress.

Authors:  Ammad Ahmad Farooqi; Kun-Tzu Li; Sundas Fayyaz; Yung-Ting Chang; Muhammad Ismail; Chih-Chuang Liaw; Shyng-Shiou F Yuan; Jen-Yang Tang; Hsueh-Wei Chang
Journal:  Tumour Biol       Date:  2015-07-19

Review 10.  Mutant p53 in cancer: new functions and therapeutic opportunities.

Authors:  Patricia A J Muller; Karen H Vousden
Journal:  Cancer Cell       Date:  2014-03-17       Impact factor: 31.743

  10 in total
  3 in total

Review 1.  Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer.

Authors:  Shengliang Zhang; Lindsey Carlsen; Liz Hernandez Borrero; Attila A Seyhan; Xiaobing Tian; Wafik S El-Deiry
Journal:  Biomolecules       Date:  2022-04-06

Review 2.  Therapeutic Targeting of Autophagy in Pancreatic Ductal Adenocarcinoma.

Authors:  Alexander G Raufi; Nicholas R Liguori; Lindsey Carlsen; Cassandra Parker; Liz Hernandez Borrero; Shengliang Zhang; Xiaobing Tian; Anna Louie; Lanlan Zhou; Attila A Seyhan; Wafik S El-Deiry
Journal:  Front Pharmacol       Date:  2021-11-30       Impact factor: 5.810

3.  Integrative analysis of dysregulated lncRNA-associated ceRNA network reveals potential lncRNA biomarkers for human hepatocellular carcinoma.

Authors:  Chengyun Li; Wenwen Zhang; Hanteng Yang; Jilian Xiang; Xinghua Wang; Junling Wang
Journal:  PeerJ       Date:  2020-03-11       Impact factor: 2.984

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.